|
|
 Previous Article | Table of Contents | Next Article 
Hexamethylene bisacetamide in myelodysplastic syndrome and acute
myelogenous leukemia: a phase II clinical trial with a differentiation-
inducing agent
M Andreeff, R Stone, J Michaeli, CW Young, WP Tong, H Sogoloff, T Ervin, D Kufe, RA Rifkind and PA Marks
Department of Molecular Pharmacology, Memorial Sloan-Kettering Cancer
Center, New York, NY 10021.
Hexamethylene bisacetamide (HMBA) is a potent inducer of differentiation of
a number of transformed cell lines in vitro. We report results of a phase
II clinical trial in 41 patients with myelodysplastic syndrome (MDS) or
acute myelogenous leukemia (AML) to whom HMBA was administered by
continuous infusion for 10 days and repeated after an interval of 18 to 75
days. HMBA induced a complete remission (CR) in three patients and a
partial remission (PR) in six patients. The median duration of CR was 6.8
months (range 1.3 to 16 months) and 3.7 months for PR (range 1 to 7
months). No significant difference was observed between responders and
nonresponders with respect to the mean HMBA plasma levels, which were 0.86
+/- 0.04 mmol/L and 0.87 +/- 0.12 mmol/L, respectively. In certain patients
morphologic and chromosome analyses provided evidence that HMBA induced
differentiation of transformed hematopoietic precursors. The most prominent
toxicity was thrombocytopenia, generally reversible on cessation of
administration of HMBA.
Volume 80,
Issue 10,
pp. 2604-2609,
11/15/1992
Copyright © 1992 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Ogawa, T. Hayashi, M. Tokunou, K. Nakachi, J. E. Trosko, C.-C. Chang, and N. Yorioka
Suberoylanilide Hydroxamic Acid Enhances Gap Junctional Intercellular Communication via Acetylation of Histone Containing Connexin 43 Gene Locus
Cancer Res.,
November 1, 2005;
65(21):
9771 - 9778.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Xu, F. Guidez, A. Glasow, D. Chung, K. Petrie, K. Stegmaier, K.-K. Wang, J. Zhang, Y. Jing, A. Zelent, et al.
Benzodithiophenes Potentiate Differentiation of Acute Promyelocytic Leukemia Cells by Lowering the Threshold for Ligand-Mediated Corepressor/Coactivator Exchange with Retinoic Acid Receptor {alpha} and Enhancing Changes in all-trans-Retinoic Acid-Regulated Gene Expression
Cancer Res.,
September 1, 2005;
65(17):
7856 - 7865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z.-y. Wang
Ham-Wasserman Lecture: Treatment of Acute Leukemia by Inducing Differentiation and Apoptosis
Hematology,
January 1, 2003;
2003(1):
1 - 13.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Silverman, E. P. Demakos, B. L. Peterson, A. B. Kornblith, J. C. Holland, R. Odchimar-Reissig, R. M. Stone, D. Nelson, B. L. Powell, C. M. DeCastro, et al.
Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
J. Clin. Oncol.,
May 15, 2002;
20(10):
2429 - 2440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Bruserud, B. T. Gjertsen, and T.-s. Huang
Induction of Differentiation and Apoptosis-- A Possible Strategy in the Treatment of Adult Acute Myelogenous Leukemia
Oncologist,
December 1, 2000;
5(6):
454 - 462.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
V. R. Agarwal, E. D. Bischoff, T. Hermann, and W. W. Lamph
Induction of Adipocyte-specific Gene Expression Is Correlated with Mammary Tumor Regression by the Retinoid X Receptor-Ligand LGD1069 (Targretin)
Cancer Res.,
November 1, 2000;
60(21):
6033 - 6038.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. A. Ruefli, M. J. Smyth, and R. W. Johnstone
HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance
Blood,
April 1, 2000;
95(7):
2378 - 2385.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Heaney and D. W. Golde
Myelodysplasia
N. Engl. J. Med.,
May 27, 1999;
340(21):
1649 - 1660.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. M. Richon, S. Emiliani, E. Verdin, Y. Webb, R. Breslow, R. A. Rifkind, and P. A. Marks
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
PNAS,
March 17, 1998;
95(6):
3003 - 3007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Siegel, X. Zhang, R. Feinman, T. Teitz, A. Zelenetz, V. M. Richon, R. A. Rifkind, P. A. Marks, and J. Michaeli
Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells
PNAS,
January 6, 1998;
95(1):
162 - 166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Kouides and J. M. Bennett
Understanding the Myelodysplastic Syndromes
Oncologist,
December 1, 1997;
2(6):
389 - 401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
